A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1068

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG: PF-06801591
DRUG: Bacillus Calmette-Guerin

Sponsor

Pfizer